APTINYX INC (APTX) Stock Price, Forecast & Analysis
NASDAQ:APTX • US03836N1037
APTX Key Statistics, Chart & Performance
The current stock price of APTX is 0.061 USD. In the past month the price decreased by -53.29%. In the past year, price decreased by -89.72%.
APTX Technical Analysis
APTX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to APTX. While APTX seems to be doing ok healthwise, there are quite some concerns on its profitability.
APTX Financial Highlights
Over the last trailing twelve months APTX reported a non-GAAP Earnings per Share(EPS) of -0.96. The EPS increased by 13.51% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0.58 |
APTX Forecast & Estimates
8 analysts have analysed APTX and the average price target is 0.51 USD. This implies a price increase of 736.07% is expected in the next year compared to the current price of 0.061.
For the next year, analysts expect an EPS growth of 50.06% and a revenue growth -100% for APTX
APTX Ownership
APTX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.67 | 390.397B | ||
| AMGN | AMGEN INC | 16.25 | 197.396B | ||
| GILD | GILEAD SCIENCES INC | 17.02 | 193.298B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.81 | 117.026B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.87 | 81.87B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.05 | 42.576B | ||
| INSM | INSMED INC | N/A | 31.656B | ||
| NTRA | NATERA INC | N/A | 29.322B | ||
| BIIB | BIOGEN INC | 12.85 | 28.06B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.16 | 20.49B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About APTX
Company Profile
Aptinyx Inc. is a clinical stage biopharmaceutical company, which engages in discovery, development, and commercialization of transformative therapies for disorders of the brain and nervous system. The company is headquartered in Evanston, Illinois and currently employs 12 full-time employees. The company went IPO on 2018-06-21. The firm is focused on the discovery, development, and commercialization of proprietary, synthetic small molecules for the treatment of brain and nervous system disorders. The firm focuses on targeting and modulating N-methyl-D-aspartate receptors, (NMDArs), which are vital to the normal and effective function of the brain and nervous system. The firm's NYX-783 is in Phase 1 clinical development for the treatment of opioid use disorder (OUD), and in preclinical development for the treatment of alcohol use disorder. NYX-783 modulates NMDA receptors to increase glutamatergic activity in key regions and may act to enhance extinction learning and alleviate the emotional symptoms of opioid withdrawal. The firm's NMDAr modulator discovery platform builds on NMDAr biology. The platform has the potential to develop into a broad pipeline and product portfolio across an array of disorders of the brain and nervous system.
Company Info
APTINYX INC
1801 Maple Ave Ste 4300
Evanston ILLINOIS 60201 US
CEO: Norbert G. Riedel
Employees: 12
Phone: 18478710377.0
APTINYX INC / APTX FAQ
What does APTINYX INC do?
Aptinyx Inc. is a clinical stage biopharmaceutical company, which engages in discovery, development, and commercialization of transformative therapies for disorders of the brain and nervous system. The company is headquartered in Evanston, Illinois and currently employs 12 full-time employees. The company went IPO on 2018-06-21. The firm is focused on the discovery, development, and commercialization of proprietary, synthetic small molecules for the treatment of brain and nervous system disorders. The firm focuses on targeting and modulating N-methyl-D-aspartate receptors, (NMDArs), which are vital to the normal and effective function of the brain and nervous system. The firm's NYX-783 is in Phase 1 clinical development for the treatment of opioid use disorder (OUD), and in preclinical development for the treatment of alcohol use disorder. NYX-783 modulates NMDA receptors to increase glutamatergic activity in key regions and may act to enhance extinction learning and alleviate the emotional symptoms of opioid withdrawal. The firm's NMDAr modulator discovery platform builds on NMDAr biology. The platform has the potential to develop into a broad pipeline and product portfolio across an array of disorders of the brain and nervous system.
What is the current price of APTX stock?
The current stock price of APTX is 0.061 USD. The price decreased by -39% in the last trading session.
Does APTX stock pay dividends?
APTX does not pay a dividend.
What is the ChartMill technical and fundamental rating of APTX stock?
APTX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the market expecting APTX stock to perform?
8 analysts have analysed APTX and the average price target is 0.51 USD. This implies a price increase of 736.07% is expected in the next year compared to the current price of 0.061.
Can you provide the growth outlook for APTINYX INC?
The Revenue of APTINYX INC (APTX) is expected to decline by -100% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the ownership details for APTX stock?
You can find the ownership structure of APTINYX INC (APTX) on the Ownership tab.